This article is more than 5 years old. Information may no longer be current.
Cardiology Today’s top arrhythmia stories of 2018
Healio Cardiology has compiled a list of the top 10 most-read articles on arrhythmia disorders posted in 2018.
New innovations in technology, guidelines and approaches and revelations in trials were among the subjects readers were most interested in.
Read on and weigh in by commenting on this article or emailing the Editors at cardiology@healio.com.
Cardiologists react to new Apple Watch ECG capabilities
Upon Apple’s announcement on Sept. 12 that the redesigned Apple Watch Series 4 will feature an electrical heart rate sensor that can take an electrocardiogram using a new ECG app, Cardiology Today spoke with cardiologists about the impact of this new technology and how it may be used in clinical practice. Read more
Pool ed analysis: Apixaban confers best outcomes in nonvalvular AF
In a pooled analysis of data from CMS and four commercial payers, apixaban (Eliquis, Bristol Myers Squibb/Pfizer) was associated with lower risk for stroke/systemic embolism and major bleeding compared with dabigatran (Pradaxa, Boehringer Ingelheim) and rivaroxaban (Xarelto, Janssen/Bayer) in patients with nonvalvular atrial fibrillation. Read more
CABANA: Ablation an ‘acceptable treatment strategy’ for AF
In patients with atrial fibrillation, catheter ablation conferred better outcomes compared with drug therapy in on-treatment and per-protocol analyses, but not in an intention-to-treat analysis, according to the results of the CABANA trial. Read more
New BP threshold identifies risk in patients with AF, hypertension
Patients with atrial fibrillation who also have hypertension as defined by the 2017 guideline had increased risk for major CV events, leading researchers for a new study to state that “the new BP threshold is beneficial for timely diagnosis and intervention.” Read more
NODE-1: Etripamil may halt supraventricular tachycardia
Etripamil, a novel fast-acting calcium channel blocker administered via nasal spray, quickly terminated supraventricular tachycardia, according to the results of the NODE-1 trial. Read more
Rivaroxaban reduces stroke, systemic embolism in frail patients vs. warfarin
Among patients with nonvalvular atrial fibrillation and frailty, rivaroxaban was associated with reduced risk for stroke and systemic embolism compared with warfarin, according to the results of a cohort study. Read more
Apixaban may be safer than warfarin in AF, end-stage renal disease
USPSTF: Evidence insufficient on benefits, risks of ECG to diagnose AF
The U.S. Preventive Services Task Force found inadequate evidence assessing the benefits and harms of screening for atrial fibrillation with ECG in patients aged 65 years and older with previously undiagnosed AF, according to a recommendation statement published in JAMA. Read more
FDA categorizes recall of ICDs, CRT-Ds as class I
The FDA announced it has identified a recall of certain implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators made by Medtronic as class I, the most serious kind. Read more
LEADLESS: Miniature pacemaker effective at 3 years, but battery to be redesigned
A miniature leadless pacemaker was safe and effective at 3 years in the first-in-human LEADLESS study, according to a research letter published in Circulation. Read more